Eli Lilly vs Merck: Where the Pharma Re-Rating Goes Next
LLY trades at 26.7x forward on GLP-1 growth. MRK trades at 22x forward on a Keytruda cliff. The Valuation Desk compares the two franchises on durability, pipeline, and execution to identify the next leg of pharma outperformance.